Brief: Jasper Therapeutics Reports Positive Data From Spotlight Study Of Briquilimab
14/10/2024 12:36
Oct 14 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS REPORTS POSITIVE DATA FROM SPOTLIGHT
STUDY
OF BRIQUILIMAB IN CHRONIC INDUCIBLE URTICARIA
* JASPER THERAPEUTICS INC - NO SERIOUS ADVERSE EVENTS
REPORTED
* JASPER THERAPEUTICS INC - FULL DATA FROM SPOTLIGHT STUDY
EXPECTED IN FIRST HALF OF 2025
Source text for Eikon: ID:nGNX5qC020
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma